Ozempic and Wegovy reshape consumer eating habits
US fast-food giant McDonald’s is testing and adjusting menu items to respond to shifting consumer habits driven by GLP-1 medications such as Ozempic and Wegovy, according to Business Insider.
These treatments suppress appetite, leading consumers to choose smaller portions, higher-protein options and fewer sugary snacks and beverages, said CEO Chris Kempczinski.
Read also: Diverzum, the largest Gen Z loyalty app in CEE, launches in Romania
Executive Jill McDonald noted that the current menu already includes options aligned with these preferences, such as Snack Wraps and McCrispy chicken strips. Additional products are reportedly under development.
An EY consumer products expert cited by Business Insider estimates that around 10% of the US population currently uses a GLP-1 medication, prompting structural shifts across the food and beverage industry. Companies such as General Mills and Conagra Brands are introducing smaller portions and repositioning products as “GLP-1 Friendly”.
Meanwhile, Shake Shack has launched its “Good Fit Menu” with protein-rich options, including lettuce-wrapped burgers.
McDonald’s reported a 5.7% increase in global comparable sales last quarter and revenues of approximately $7 billion, with investors viewing menu adaptation as a strategic opportunity.
Photo: BBC
UK
IT
ES
DE
FR
RO
PT
HU
